Probucol: revisiting as a multifaceted therapeutic agent in atherosclerosis
Atherosclerotic cardiovascular disease (ASCVD) is known to be driven by chronic inflammation and pro-atherogenic dyslipidemia and remains as one of the leading causes of mortality globally. Despite the success of current lipid-lowering therapies, a significant residual inflammatory risk persists, hi...
Na minha lista:
| Principais autores: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2026-01-01
|
| Colecção: | Frontiers in Pharmacology |
| Assuntos: | |
| Acesso em linha: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1704983/full |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|